GlassScriptPhysician profile
Rufino Rosal
NPI 1528152469
$1,720.76
in general payments reported to CMS, 2019-2025
28 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $425 · 2021: $285 · 2022: $70.39 · 2023: $224 · 2024: $104 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $241.02 | 2019-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Insulet Corporation | $190.14 | 2020-2024 | Omnipod |
| Amarin Pharma, INC. | $153.64 | 2019-2022 | |
| Novo Nordisk INC | $136.28 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $128.64 | 2019-2021 | |
| Abbott Laboratories | $112.39 | 2023-2025 | Freestyle Libre 3, Eterna, Proclaim |
| Sanofi-Aventis U.S. LLC | $87.93 | 2020-2024 | |
| Tris Pharma INC | $87.58 | 2020-2023 | Dyanavel Xr |
| Shire North American Group INC | $74.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.34 | 2019-2021 | |
| Glaxosmithkline, LLC. | $61.43 | 2019-2025 | Penmenvy, Pediarix, Bexsero |
| Corcept Therapeutics | $50.08 | 2019-2023 | Korlym |
| Astrazeneca Pharmaceuticals LP | $34.89 | 2019 | |
| Dexcom, INC. | $34.25 | 2021 | |
| Becton, Dickinson and Company | $30.06 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $27.78 | 2025 | |
| Ironshore Pharmaceuticals INC. | $25.49 | 2019 | |
| Amneal Pharmaceuticals LLC | $25.31 | 2023 | Unithroid |
| Valeritas, INC. | $19.14 | 2019 | |
| Seqirus USA INC | $18.87 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.45 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $16.00 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $14.72 | 2019 | |
| Abbvie INC. | $14.53 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.50 | 2021 | |
| Eisai INC. | $12.90 | 2021 | |
| Ibsa Pharma INC. | $12.55 | 2020 | |
| Sobi, INC | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rufino Rosal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.